Skip to content
Clinical Trials – home

Instytut Diabetologii Sp. z o.o.

Research site

Poland Ul. Raclawicka 129/2u, 02-117 Warsaw, Poland

  • 3 trials recruiting
  • Obesity · Type 2 diabetes mellitus · Overweight
  • Adults and children

About Specializations

Instytut Diabetologii Sp. z o.o. in Warsaw, Poland specialises in clinical trials of conditions such as Obesity, Type 2 diabetes mellitus, Overweight, Diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiometabolic Disease Research

At Instytut Diabetologii Sp. z o.o. in Warsaw, clinical trials are focused on cardiovascular diseases and nutritional and metabolic diseases, with a strong emphasis on metabolism. The studies mainly examine type 2 diabetes mellitus, obesity, and related high-risk conditions, aiming to improve long-term disease control and support better health outcomes.

  • Trials evaluating new approaches for type 2 diabetes alongside cardiovascular risk reduction
  • Research on weight management in overweight and obesity
  • Studies exploring how metabolic treatment can improve glycemic control and overall cardiometabolic health

Several projects are designed to test whether emerging therapies can better reduce body weight, improve blood sugar management, and lower the risk of major heart-related events in people with metabolic disease.

Type 1 Diabetes and Beta Cell Preservation

A major part of the research at this site centers on type 1 diabetes mellitus, especially in people newly diagnosed or in the early stages of the disease. These studies investigate whether treatment can help preserve insulin-producing cells, maintain beta cell function, and support better glucose regulation over time.

  • Studies in newly diagnosed type 1 diabetes and recent-onset disease
  • Research focused on preserving insulin production and slowing disease progression
  • Trials assessing whether investigational therapies can improve glycemic control and reduce insulin dependence

The work includes follow-up and treatment studies that look at safety, tolerability, and the potential to slow the natural decline in pancreatic function.

Obesity and Weight-Loss Studies

The site also conducts multiple trials in obesity and overweight, including studies in adolescents and adults. These trials are designed to evaluate new therapies that may help people achieve meaningful weight reduction and improve related metabolic health concerns.

  • Research on treatment options for overweight and obesity
  • Studies in people with excess body weight and related conditions such as type 2 diabetes
  • Trials assessing the effectiveness of new therapies for body weight reduction

These studies are aimed at finding safer and more effective ways to support weight management, with attention to both standalone obesity care and obesity linked to diabetes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Raclawicka 129/2u02-117 WarsawPoland
Recruiting now
3 trials
Conditions studied
6

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

15 clinical trials

Obesity+1

Recruiting

Study on the Effectiveness and Safety of Orforglipron for Weight Management in Adolescents with Obesity or Overweight

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Sab Biotherapeutics Inc.

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Type 2 diabetes mellitus+2

Not recruiting

A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Not recruiting

Evaluation of Tirzepatide Versus Placebo in Adolescents with Obesity or Overweight and Weight-Related Comorbidities: A Randomized, Double-Blind Clinical Trial

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Colecalciferol
  • Sponsor:Diamyd Medical AB

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.